The field of vascularized composite allograft (VCA) to achieve its full potential will require induction of tolerance. This review will introduce a new method of potential inducing tolerance in hand transplantation.
INTRODUCTION
As skin transplants evoke very powerful rejection in preclinical transplant models, it came as a surprise to many, including several coauthors of this review, that composite tissue allografts, for example, limb and face allografts, can be engrafted using immunosuppressive protocols that were developed for use in recipients of conventional kidney, liver, heart and pancreas transplants. Rejection, although frequent, is not nearly as formidable a barrier for success as many had predicted. The development of the multidisciplined infrastructure required to perform the surgery and posttransplant care has been the greater challenge to success [1 & ,2]. A few 'wounded warriors', victims of severe combat injuries, are recipient-pioneers of hand transplants [3] . Should young, otherwise healthy individuals be subject to life-long immunosuppression to save a limb, particularly, a hand allograft? It is reasonable, therefore, to attempt to foster a state of donor-specific transplant tolerance as a means to avoid the inevitable toxicity of life-long immunosuppression. Taking into consideration that limb transplants, although technically amazing and providing profound rehabilitation, do not save lives, we must ask which potentially tolerizing protocols are the best fit for limb transplant recipients? The following is an attempt to address these all-important issues.
ETHICAL CONSIDERATIONS FOR TOLERANCE INDUCTION IN HAND TRANSPLANT RECIPIENTS
Life-long maintenance immunotherapy cannot be easily justified as a means to preserve the engraftment of hand transplants as hand transplants are not 'life-saving' and prosthetic hands provide acceptable, albeit not perfect, function. Successful application of tolerizing strategies would lessen the risk for opportunistic infectious disease and cancer, avoid off-target nonimmune system drug toxicity (for example, kidney toxicity by calcineurin inhibitors) and prevent chronic rejection, thereby improving graft and patient survival.
Hence, many in the field regard tolerance induction as not merely an interesting exercise but instead crucial to the ability to avoid life-long immunosuppression and thus a necessity for wider application of hand transplantation. Efforts to achieve tolerance must be safe without undue risk for toxicity or loss of graft function although it seems unlikely that not every hand transplant recipient will be rendered tolerant using 'well tolerated' therapeutic tools currently in hand. It is notable that some transplant patients, such as select liver transplant recipients, can undergo drug withdrawal and yet maintain transplant function indefinitely [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
For example, drug withdrawal can be successful with little risk of graft loss. Hover monitoring for liver fibrosis is necessary. Withdrawal is not always tolerated. It is possible that properly supervised hand transplant recipients can also be withdrawn from immunosuppression, if treated with low-dose IL-2 at the proper time, and by monitoring of skin rejection.
Should treatment to induce tolerance fail shortterm or long-term in hand transplant recipients, the diagnosis of early hand transplant rejection can be made far more readily than in recipients of conventional kidney, heart, lung or liver transplants and the opportunity for prompt restoration of immunosuppressive drug therapy is obvious. The diagnosis of rejection of conventional kidney, liver and other transplants is made in the course of a work up for graft injury/dysfunction or through random surveillance biopsies. Thus, rejection is not readily detected at an early stage. Early rejection of hand transplants involves the skin and rejection-related changes are obvious upon physical examination ( Fig. 1 ). However, monitoring of deep tissues, such as arteries, will also be mandatory. Skin is not always a perfect marker of rejection [15] .
The diagnosis of rejection can often be confirmed or refuted through pathologic analysis of small skin biopsies. As a consequence, antirejection therapy can be quickly reinstituted enabling salvage of the hand transplant. Interestingly, hand transplant patients often experience many more rejection episodes than recipients of conventional transplants, yet graft loss is uncommon in hand transplant as compared with conventional transplant recipients. This issue is discussed in companion articles in this issue.
Potential tolerizing therapies
Transplant tolerance can be induced through one of two broad mechanisms, either total deletion of antidonor effector T cells or donor-specific dominant immunoregulation. Perhaps, the most durable form of transplant tolerance is created through selective total and durable deletion of recipient antidonor T cell clones. In many mouse models in which total deletion of antidonor T cell clones can be obtained and inhuman recipients of successful hematopoietic cell allograft who have been treated for hematopoietic malignancies, the recipients can later be successfully transplanted with organ allografts from the hematopoietic stem cell donor in the absence of maintenance immunosuppressive therapy. To date, clinical protocols that employ donor hematopoietic stem cells to achieve stable multilineage mixed hematopoietic cell chimerism have shown promise for the induction of kidney allograft tolerance [16, 17] .
The appropriateness of this approach for hand transplants is diminished by the risk for graft versus
KEY POINTS
Hand transplant recipients should not receive life-long immunosuppressive therapy, as the transplants are not life-sustaining.
Tolerance induction, not maintenance immunosuppressive therapy, is the goal in this patient population.
To this end and recognizing the adverse influence of posttransplant inflammation on tolerance, we will employ delayed induction of tolerizing protocols.
Low not high-dose IL-2 will serve as the linchpin of our tolerizing regimen. host disease. The use of donor hematopoietic stem cells as the facet of treatment inherently carries this risk in the immunosuppressed hand transplant recipient, a complication that may not be consistent with the mandate for well tolerated treatment in recipients of a transplant that is not life-saving or life-sustaining. We acknowledge that this is an opinion, not a fact. A secondary consideration inherent in tolerance produced by hematopoietic stem cell protocols is the difficulty of achieving tolerance in human leukocyte antigen (HLA)mismatched individuals.
Another means of producing transplant tolerance is to produce dominant donor-directed immunoregulation, a state in which overall recipient antidonor immunity is marked by the functional superiority of donor-reactive regulatory T cells (Treg) over donor-reactive effector T cells. Donorreactive Treg hold donor-reactive effector T cells in check and thereby the immune system protects not attacks the transplant. Paradoxically, this state might be responsible for the ability to withdraw immunosuppression in recipients who have been given donor hematopoietic stem cells but transient and modest rather than durable and robust mixed chimerism has been established [16] . In preclinical models, other therapeutic strategies, such as costimulation blockade, have been used to achieve this end and evolution of this state [18] with convention treatment is almost certainly responsible for the ability to successfully withdraw immunosuppressive from select transplant recipients long term.
BARRIERS TO IMMUNE TOLERANCE IN PATIENTS WITH ORGAN OR TISSUE TRANSPLANTS: MEMORY B AND T CELLS
Donor-reactive memory-type immunity can result from immunization with microbes, a previous transplant or transfusion when the new transplant shares antigens or antigenic epitopes with these previous antigenic exposures. Following transplantation, the ability to detect early rejection of conventional (kidney, liver, heart, pancreas or lung) transplants is compromised by the lack of early clinical signs of rejection. As a consequence, memory-type antidonor immunity is well established by the time that a clinical diagnosis of rejection is established and treated. Although treatment may suppress the action of donor-reactive T cells, they can be reactivated if an inflammatory state develops. There are only a few studies in which surveillance biopsies of kidney transplants have been undertaken. These studies demonstrate that it is not uncommon for transplant biopsies to reveal typical histopathologic evidence of 'subclinical' rejection despite an absence of conventional clinical evidence or even suspicion of ongoing rejection. In recipients with 'subclinical rejection', long-term outcomes are compromised. Unlike conventional transplants, the hand transplant can be visually inspected and early signs of rejection are clearly evident and the diagnosis can often be confirmed or refuted by biopsy. Surprisingly, the incidence of diagnosis is frequent yet long-term outcomes are excellent [19] . Frequent rejections in recipients of conventional transplant are ominous and associated with poor outcomes. As surveillance biopsies reveal that 'subclinical rejection' episodes are missed in conventional transplants and that this situation leads to poor outcomes, it seems reasonable to speculate that the ease of diagnosis of rejection in hand transplants leads to a better response to treatment long term.
Early diagnosis also should reduce the number of donor-reactive memory type immune cells that accrue in the recipient. As memory cells are far less responsive to treatment or the tolerizing effects of Treg than naïve immune cells, a reduction in the burden of antidonor-directed memory cells leads to excellent long-term outcomes and almost certainly enhances the opportunities for successful minimization and withdrawal of immunosuppressive drug therapy.
THE PERITRANSPLANT INFLAMMATORY RESPONSE: IMPLICATIONS FOR TOLERANCE INDUCTION
Ischemia-reperfusion injury is an inherent component of the recipient response to organ or tissue transplants and is evident even in syngeneic transplants. Of course, this situation is particularly problematic in deceased donor transplants. It seems certain that ischemia-perfusion injury will be a problem for tolerance induction in limb transplants [20] . As a consequence of ischemia-reperfusion injury, expression of proinflammatory cytokines and chemokines, complement activation, a prothrombotic state and very rapid influx of innate immune cells ensues. This situation exerts an adverse ripple effect upon the nature of recipient antidonor immunity. It is now abundantly clear that the phenotype assumed by adaptive immunity is strongly influenced by the state of innate immunity [21, 22] . Naïve T cells that recognize antigen within a microenvironment devoid of proinflammatory cytokines are prone to become Treg through the unopposed action of transforming growth factor beta (TGF)-b, a constitutively expressed cytokine [23, 24] . With ischemia-reperfusion injury, expression of IL-6 or IL-21 and other proinflammatory cytokines is induced. The presence of IL-6 or IL-21 negate the ability of TGF-b to promote polarization of naïve T cells to the Treg phenotype and also promote polarization of antigen-activated naïve CD4 þ T cells to the highly inflammatory and cytodestructive Th17 phenotype [25] [26] [27] . The negation of induction to Treg is likely more detrimental than polarization to the Th17 phenotype for induction of transplant tolerance. Other proinflammatory molecules impact upon the nature of T cell polarization occurring with antigen stimulation (Fig. 2) . IL-12, a monokine, and IL-4 promote polarization of naïve CD4 þ T cells following antigen activation to the Th1 and Th2 phenotypes, respectively. The development of drug-free immune tolerance in the absence of complete eradication of antigen-specific clones is dependent upon an enduring functional ? FIGURE 2. The differentiation and conversion of CD4 þ T cells is determined by the cytokines present in the environment. Naive CD4 þ T cells have plasticity to differentiate into helper T cell (Th)1, Th2, Th17 and Treg. Upon antigen activation, naïve CD4 T cells respond to cytokines produced by innate immune cells, such as IL-12 and interferon gamma (IFN)-g, which are important for Th1 cell differentiation, and IL-4, which is crucial for Th2 cell differentiation. TGF-b together with IL-6 induces Th17 cell differentiation, whereas Treg differentiation is induced by TGF-b and IL-2. It is important to note that these T differentiated cell phenotypes also have plasticity. When IL-6/IL-21 is present, such as in the episode of autoimmune inflammation, Treg phenotype can change to Th17, therefore losing the immunoregulatory functions. Recently, it was also found that Treg can become Th1 and Th2 in certain conditions. Th17, on the other hand, can become Th1 and Th2, respectively, in the milieu of IL-12 and IL-4. Treg, regulatory T cells. supremacy of antigen-specific Treg over conventional antigen-reactive immune cells. Hence, the microenvironment created by ischemia-reperfusion injury and inflammatory damage to the transplant in the peritransplant period is not at all conducive to the creation of transplant tolerance because of the adverse influence of this environment upon polarization of T cells to the Treg phenotype.
The duration of a tolerance unfriendly posttransplant inflammatory state in a living donor nonhuman primate model as evidenced by expression of proinflammatory cytokines, chemokines and resistance to tolerance induction lasts for months [28 && ]. Yet, time-related resolution of the tolerance-unfriendly proinflammatory state achieved through delayed application of tolerizing protocols affords a far better opportunity to establish more enduring mixed chimerism and tolerance than application in the immediate posttransplant period [28 && ]. Similarly, liver transplants have been long known to be far more amenable to tolerance induction than other conventional organ transplants and it is possible to discontinue immunosuppression in a substantial number of patients who have safely undergone dose minimization of their immunosuppressive drugs [29 && ,30 && ]. More recently, it has become apparent that the ability to successfully withdraw immunosuppressive drugs in liver transplant recipients is related to the duration of engraftment at which drug withdrawal is attempted [30 && ]. In order to induce transplant tolerance in patients lacking detrimental inflammation, a strategy that we will embrace in our hand transplant program, we will utilize standard therapy initially and wait until detrimental, tolerance-negating inflammation resolves before trying to induce tolerance. Recall that the presence of IL-6 in microenvironment in which naïve T cells recognize antigen negates the ability to generate Treg. Moreover, expression of IL-6 and other proinflammatory cytokines, often expressed during early acute rejection episodes, disrupts the phenotype of established Treg and turns these former regulatory cells into aggressive effector T cells. Waiting to create tolerance at a time point beyond the early period in which hand transplants are rejection prone may also prove beneficial. Again, this will be our core strategy to maximize the possibilities to generate antigenspecific regulatory T and hence donor-specific tolerance. Our patients will be carefully monitored for expression of proinflammatory cytokines during and after the withdrawal of conventional immunosuppressive therapy. Should robust inflammation accompany drug withdrawal, we will consider adding therapy to selectively neutralize these cytokines.
Corticosteroids, agents that broadly block inflammation, will not be used for lack of specificity in this regard.
What else can be done to maximize the potential for generating and maintaining the enduring supremacy of donor-reactive Treg over donor-reactive effector T cells as a means to achieve durable transplant tolerance? In our effort, we will use shortterm low-dose IL-2 therapy to bridge the period between the total withdrawal of conventional immunosuppression and absolute freedom from drugs. Our strategy is informed by the knowledge that the meta-stable phenotype of Treg and their survival is IL-2 dependent. IL-2 treatment should, if properly administered, strengthen the molecular and functional phenotype and durability of Treg and hence help tilt the balance of immunity more firmly toward tolerance.
Nonetheless, IL-2 therapy will cause unnecessary proinflammatory side-effects and as a consequence fail to tilt immunity toward tolerance unless such therapy is nuanced and carefully conceived [31 && ,32,33
&&
]. Low-doses, not high-doses of IL-2 are required to achieve selective targeting of Treg and thereby achieve the best outcomes. Treg express the tri-molecular, high-affinity IL-2 receptor. The high-affinity IL-2 receptor consists of the Janus kinase/transducer and activated transcription (JAK/STAT) signaling common chain, a trans-membrane protein that is an all-important component of receptors for each of the T cell growth factors, including IL-2, IL-4, IL-7, IL-15 and IL-21 [31 && ,32]. The IL-2 receptor as well as the tri-molecular IL-15 receptor include a beta chain [31 && ,32,34] . Recalling that Treg are CD25 high , the third component of the high-affinity IL-2 receptor also includes the IL-2 receptor-specific chain also known as CD25. The tri-molecular, high-affinity IL-2 receptor responds to IL-2 concentrations as low as 10 -11 to 10 -12 M. Newly activated T cells transiently express tri-molecular high-affinity IL-2 receptors, and IL-2 serves as an apparent death factor for these cells [35] . Significantly higher concentrations of IL-2, that is, 10 -9 M, stimulate a variety of innate immune cells and memory T cells. These features result in highly undesirable side-effects resulting from an out-pouring of inflammatory cytokines and tissue infiltration by activated-innate immune cells. Indeed, high doses of IL-2 probably act to inhibit tolerance induction.
RECENT FINDINGS
Evidence that short-term treatment with low doses of IL-2 or a long-lived IL-2 immunoglobulin (Ig) can tilt the balance of immunity from tissue destructive to tolerance come from preclinical demonstrations in the NOD mouse model of type 1 diabetes [36] , islet transplantation in the daunting model in which type 1 diabetes mice are transplanted with allogeneic islets [37] and in the cynomolgus islet allograft model [33 && ]. More recently, low-dose IL-2 therapy has achieved remarkably favorable effects in humans with drug-resistant graft versus host disease and hepatitis virus-induced vasculitis [38 && ,39] .
CONCLUSION
In this review, we have described the current status of composite tissue allografts in a donor-specific transplant tolerance. Special circumstances inherent in hand transplantation favor attempts to induce tolerance. Considering the limited success of conventional treatments, low-dose IL-2-based therapy is likely a viable option.
